Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06420323

NovoX®Cup as Primary Dressing After Breast Reduction

NovoX® Cup as Primary Dressing After Breast Reduction: an Intra-individual Comparison Between Standard of Care and Oxygen-enriched Olive Oil Bra Cup

Status
Recruiting
Phase
Study type
Observational
Enrollment
20 (estimated)
Sponsor
MOSS S.p.A. · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Breast reduction is one of the most frequently performed plastic surgeries. Studies have shown that breast reduction surgery significantly improves the patients' suffering and leads to a better health-related quality of life.However, as in every surgery, there can be complications. Wound disorders, such as open wounds and skin loss account for the most commonly encountered postoperative complications. NovoX® Cup is a new single-use wound dressing that is shaped cupular in order to tightly adapt to the breast anatomy. It is internally coated with oxygen-enriched oil releasing reactive oxygen species and is free from active pharmaceutical ingredients. It is intended, among other indications, for the use in surgical wounds after oncological breast surgery, breast reconstruction and cosmetic breast surgery. In two studies, a total of 140 patients (surgical wounds after breast augmentation-mastopexy, mammary lesions) were treated successfully with NovoX® Cup and no product-related adverse events were reported.The claimed advantages sound promising but an advantage compared to established wound dressings such as sterile strips or tapes has still to be investigated. The aim of the following study is to compare the outcomes (postoperative complications, scar quality and patients' satisfaction) of breast reduction and application of the wound dressing NovoX® Cup in comparison to already established wound closure systems 2 weeks and 3 months after surgery.

Detailed description

A prospective intra-individually controlled cohort study. One breast will be chosen (left or right) to be treated with the NovoX®-Cup. The other breast will serve as the "standard of care" control. Randomization within this clinical investigation will be done intra-individually in a 1:1 ratio.

Conditions

Interventions

TypeNameDescription
DEVICETreatment with NovoX® CupNovoX® Cup treatment
DEVICETreatment with Omnistrip®Omnistrip® treatment

Timeline

Start date
2024-07-25
Primary completion
2026-04-01
Completion
2026-04-01
First posted
2024-05-20
Last updated
2025-04-10

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT06420323. Inclusion in this directory is not an endorsement.